Premium
Use of psoralen therapies obtained abroad in two children with Vitiligo
Author(s) -
Bell Katheryn A.,
Saardi Karl M.,
Norton Scott A.,
Habeshian Kaiane A.
Publication year - 2020
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.14283
Subject(s) - medicine , vitiligo , dermatology , psoralen , malignancy , phototoxicity , treatment modality , alopecia areata , sun exposure , surgery , pathology , dna , biochemistry , chemistry , genetics , in vitro , biology
We describe two American‐born children with vitiligo, each of whom travelled to their family's ancestral home (India and Ethiopia), where their skin conditions were treated with PUVAsol, which involves the use of topical or oral psoralens followed by exposure to natural sunlight. Both children experienced modest repigmentation and were subsequently seen in our dermatology clinics. PUVAsol may be an attractive treatment option for some families, but there are potentially serious side effects including phototoxicity and cutaneous malignancy. Dermatologists should be aware of the existence of this treatment modality as well as its complications.